Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuL001 in Combination With Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT07210047Phase 2Recruiting
- Sponsor
- HuniLife Biotechnology, Inc.
- Start
- Aug 2025
- Primary completion
- Nov 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HuL001 in multiple myeloma (MM), sponsored by HuniLife Biotechnology, Inc. Primary endpoint: Myeloma responses at 8 months. Started Aug 2025; status: recruiting.
02
Drugs
HuL001
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07210047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07210047.